Reconstitute in ddH2O. Store at -20ºC.
Purity was assessed by SDS-PAGE (≥85%) and by HPLC (≥85%).
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Interleukin28A, InterferonLambda 2, IL28A, IFN-Lambda 2, IFNLambda 2, Interleukin-28A, InterferonLambda2, Cytokine ZCYTO20, IFNL2, IL28, IL-28A, IFNLambda2, Interferon-Lambda 2, ZCYTO20., IL 28A, IFN Lambda 2, Interleukin 28A, Interferon Lambda 2
IL-28A is distantly related to type I interferons and the IL-10 family. Expression of IL-28A is induced by viral infection which interacts with a heterodimeric class II cytokine receptor that consists of interleukin 10 receptor, beta (IL10RB) and interleukin 28 receptor alpha . IL-28A exhibits common features with type I IFNs such as antiviral activity, antiproliferative activity and in vivo antitumour activity. IL-28A acts similarly to IFNs, but is less effective generally and has activity in a more limited range of cell lines. IL-28A induces ELR(-) CXC chemokine mRNA in human peripheral blood mononuclear cells, in an IFN-gamma-independent manner.
IL-28A produced in response to viral infection, activates both monocytes and macrophages producing a restricted panel of cytokines and therefore is an important factor in activating innate immune responses at the site of viral infection. Recombinant human IL-28A produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 175 amino acids and having a molecular mass of 19.6 kDa.